Now, Gilead has been largely shoved out of the news by Turing and other companies with similar practices, most notably Valeant Pharmaceuticals International.
Advertisement
Continue reading the main story
Unlike many other countries, the United States does not control drug prices, making the American market a big source of profits for drug makers worldwide. In the last two decades or so, price increases on existing drugs in the United States accounted for fully half the growth of the entire multinational pharmaceutical industry, said Richard Evans, an analyst at SSR Health, a stock analysis company.